Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view
- 5 June 2013
- journal article
- letter
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 72 (1) , 273-274
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Treatment‐related morbidity and toxicity of CRS and oxaliplatin‐based HIPEC compared to a mitomycin and doxorubicin‐based HIPEC protocol in patients with peritoneal carcinomatosis: A matched‐pair analysisJournal of Surgical Oncology, 2012
- Appraisal of peritoneal cavity’s capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapySurgical and Radiologic Anatomy, 2009
- Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin CCancer Chemotherapy and Pharmacology, 2005
- Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distributionAnnals of Oncology, 2002
- Successful management of microscopic residual disease in large bowel cancerCancer Chemotherapy and Pharmacology, 1999